All In Biotech

Drug Trial Radar · NCT04064840

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

Gonadotrophin Releasing Hormone Agonist for Dual Trigger in in Vitro Fertilization and for Luteal Phase Support in Frozen-thawed Embryo Transfer

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 784 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

784

Planned (sponsor's estimate)

Start

Sep 1, 2019

Primary completion

Sep 1, 2024

Study completion May 30, 2026

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

Conditions

  • Subfertility

Interventions

  • IVF: Decapeptyl and hCGDrug

    When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

  • FET: DecapeptylDrug

    On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

  • IVF: hCG and normal salineDrug

    When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

  • FET: Normal SalineDrug

    On the day of FET, normal saline will be injected subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Live birth rateTime frame: after 22 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Obstetrics and Gynaecology

    Hong Kong, Hong Kong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.